Jay S Schneider

7PUBLICATIONS
15CO-AUTHORS
Clinical pharmacology and therapeuticsInfant and child healthPharmacogenomicsNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 15, 2026
A small molecule reduces both parkinsonism and l-dopa-induced dyskinesia in animal models of Parkinson's disease.

|Sep 19, 2024
Influences of quality of maternal care and environmental enrichment on associative memory function in rats with early life lead exposure.

Jay S Schneider, Courtney Williams, Shamaila Zafar

|Aug 28, 2023
Neurotoxicity and Outcomes from Developmental Lead Exposure: Persistent or Permanent?

Jay S Schneider

|Jun 10, 2023
GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson's Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson's Disease-Relevant Pathogenic Mechanisms.

Jay S Schneider

|May 26, 2021
A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease.

J S Schneider

|Jun 15, 2018
Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease.

Jay S Schneider

Pageof 2

Frequent Collaborators

1 joint publications

Blanca E Himes

1 joint publications

Aarash Bordbar

1 joint publications

Bernard Bloem

1 joint publications

Colton Lloyd